Biotech Innovator Smobya Secures Funding to Scale Sustainable Materials in Venlo
Venlo, Sunday 8 March 2026
A female-led consortium has backed Smobya’s relocation to Venlo to scale technology that transforms food waste into high-performance, sustainable alternatives for plastics and animal leather.
Strategic Relocation to Brightlands
In a significant move for the Dutch circular economy, the Hungarian biotech startup Smobya is set to transfer its entire team from Budapest to the Brightlands Greenport Campus in Venlo [1]. The relocation follows a strategic investment announced today, Sunday, 8 March 2026, by a consortium comprising the regional development agency LIOF, Joanna Invests, and Earthstar [1]. This capital injection is designed to accelerate the company’s transition from laboratory research to industrial application, specifically funding the construction of a demonstration plant in Limburg [1]. According to Annemoon Borst, an investment manager at LIOF, the venture faced a classic ‘chicken and egg’ scenario: a demonstration facility was essential to produce the volumes required by major fashion and textile brands, yet financing was a prerequisite for that construction [1]. The consortium’s intervention has now bridged this gap.
Industrialising Biology: The NanoTwine™ Technology
Smobya’s core innovation lies in its proprietary NanoTwine™ technology, which produces bacterial nanocellulose (BNC) on an industrial scale [1]. By utilising fermentation processes similar to those used in food production, the company transforms food waste into high-performance materials intended to replace synthetic plastics and animal leather [1]. Lídia Kuti, co-founder and CEO of Smobya, asserts that the company has successfully resolved the bottlenecks that previously confined bacterial nanocellulose to laboratory settings, creating a process that is both repeatable and scalable [1]. Maria Tapia, a founding partner at Earthstar, noted that the technology challenges the industry’s reliance on animal hides and petrochemical plastics, combining scientific curiosity with commercial drive [1].
Addressing the Investment Gender Gap
The timing of this announcement on International Women’s Day is deliberate, highlighting a concerted effort to address disparities in venture capital distribution. The transaction involves three female-led investment entities backing a female founder, Lídia Kuti, in the deeptech sector [1]. This mirrors broader challenges within the European ecosystem; Marguerite Mensonides, co-founder of the biotech firm Amplio Pharma, notes that less than 3% of venture capital in Europe is allocated to companies with female founders [2]. Amplio Pharma, which relocated from Sweden to the Netherlands in 2023, recently secured investment from ROM InWest to advance its ‘red biotech’ innovations, specifically the drug NovoBioJect for rheumatoid arthritis [2]. The parallel progress of Smobya in industrial biotechnology and Amplio Pharma in medical biotechnology underscores a growing, albeit underfunded, momentum for female-led scientific ventures in the Netherlands.